Q-omics provides the consensus-scored NAA20 profile across patient tissues and cancer cell-line models. NAA20 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, NAA20 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, NAA20 RNA expression shows 18,911 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, COAD, and UVM as cancer lineages where NAA20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NAA20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NAA20 survival associations across molecular data types. NAA20 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NAA20 RNA expression–survival associations across cancer types. High NAA20 expression shows unfavorable associations in HNSC, SCLC, LGG, LIHC, UVM and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for NAA20 RNA expression.
This table summarizes NAA20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NAA20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NAA20 shows lower tumor expression in THCA and higher tumor expression in COAD, LIHC, BLCA, STAD and HNSC. The COAD box plot shows higher NAA20 RNA expression in tumor versus normal tissue (log2 FC = +1.172, t-test p < 0.001).
This table shows molecular features associated with NAA20 in patient tissues and cancer cell lines. In patient samples, NAA20 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NAA20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SKIN.
